Literature DB >> 24151364

Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans.

Dae Hee Choi1, Sung Joon Lee, Chang Don Kang, Myoung Ok Park, Dong Wook Choi, Tae Suk Kim, Wonho Lee, Byung Ryul Cho, Yong Hoon Kim, Bong-ki Lee, Dong Ryeol Ryu, Ji Won Lee.   

Abstract

AIM: To investigate whether nonalcoholic fatty liver disease (NAFLD) affects coronary artery disease (CAD) and identify candidate mediators.
METHODS: Patients who underwent coronary angiography were consecutively recruited. The patients were classified into four groups by coronary artery stenosis: A, insignificant; B, one-vessel disease; C, two-vessel disease; and D, three-vessel disease. Abdominal ultrasonography was performed to determine the presence of a fatty liver and categorize by grade: 0, no evidence; 1, mild; 2, moderate; and 3, severe. We measured not only known CAD risk factors, but also serum insulin, HOMA-index, adiponectin, interleukin-6, tumor necrosis factor-α and high-sensitivity C-reactive protein levels.
RESULTS: Of the 134 patients who met the inclusion criteria, 82 (61.2%) had ultrasonographically diagnosed NAFLD. Among the 46 patients with CAD, 37 (80.4%) had evidence of a fatty liver. The two groups (A vs B-D) were significantly different in terms of age, total cholesterol, triglycerides, low-density lipoprotein levels and fatty liver. Coronary artery stenosis was strongly associated with fatty liver in a grade-dependent manner (P = 0.025). In binary logistic regression, NAFLD was a significant independent predictor of CAD (P = 0.03, OR = 1.685; 95%CI: 1.051-2.702). Among the candidate mediators, the serum adiponectin level showed a trend toward lowering based on CAD progression (P = 0.071).
CONCLUSION: NAFLD is an independent risk factor for CAD in a grade-dependent manner. Moreover, adiponectin might be related to the pathogenesis of NAFLD.

Entities:  

Keywords:  Adiponectin; Coronary angiography; Coronary artery disease; Insulin resistance; Nonalcoholic fatty liver disease

Mesh:

Year:  2013        PMID: 24151364      PMCID: PMC3801316          DOI: 10.3748/wjg.v19.i38.6453

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.

Authors:  Anna Wieckowska; Nizar N Zein; Lisa M Yerian; A Rocio Lopez; Arthur J McCullough; Ariel E Feldstein
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

Review 3.  Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers.

Authors:  M A Edens; F Kuipers; R P Stolk
Journal:  Obes Rev       Date:  2009-04-21       Impact factor: 9.213

4.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

5.  Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Stefano Rodella; Giacomo Zoppini; Luciano Zenari; Massimo Cigolini; Giancarlo Falezza; Guido Arcaro
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

6.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

7.  Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

Authors:  Yusuf Yilmaz; Enver Dolar; Engin Ulukaya; Semra Akgoz; Murat Keskin; Murat Kiyici; Sibel Aker; Arzu Yilmaztepe; Selim Gurel; Macit Gulten; Selim-Giray Nak
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

8.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.

Authors:  Stephen A Harrison; Sigurd Torgerson; Paul H Hayashi
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

9.  Plasma adiponectin levels and risk of myocardial infarction in men.

Authors:  Tobias Pischon; Cynthia J Girman; Gokhan S Hotamisligil; Nader Rifai; Frank B Hu; Eric B Rimm
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

Review 10.  Role of endothelial dysfunction in atherosclerosis.

Authors:  Jean Davignon; Peter Ganz
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

View more
  19 in total

Review 1.  Cardiac abnormalities in patients with nonalcoholic fatty liver disease : Insights from auxiliary examinations.

Authors:  Yu Dong; Guangsen Li
Journal:  Herz       Date:  2019-09-19       Impact factor: 1.443

Review 2.  Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis.

Authors:  Luan Rodrigues Abdallah; Ricardo Cardoso de Matos; Yves Pacheco Dias March E Souza; Débora Vieira-Soares; Gabriela Muller-Machado; Priscila Pollo-Flores
Journal:  Curr Atheroscler Rep       Date:  2020-02-04       Impact factor: 5.113

3.  Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH).

Authors:  Giada Sebastiani; Keyur Patel; Vlad Ratziu; Jordan J Feld; Brent A Neuschwander-Tetri; Massimo Pinzani; Salvatore Petta; Annalisa Berzigotti; Peter Metrakos; Naglaa Shoukry; Elizabeth M Brunt; An Tang; Jeremy F Cobbold; Jean-Marie Ekoe; Karen Seto; Peter Ghali; Stéphanie Chevalier; Quentin M Anstee; Heather Watson; Harpreet Bajaj; James Stone; Mark G Swain; Alnoor Ramji
Journal:  Can Liver J       Date:  2022-02-04

Review 4.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

5.  Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women.

Authors:  Min Kyung Kim; Chul Woo Ahn; Ji Sun Nam; Shinae Kang; Jong Suk Park; Kyung Rae Kim
Journal:  Menopause       Date:  2015-12       Impact factor: 2.953

6.  Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka.

Authors:  Nilanka Perera; Jegarajah Indrakumar; Waruni Vijitha Abeysinghe; Vihangi Fernando; W M C K Samaraweera; Jayamal Sanjaya Lawrence
Journal:  BMC Cardiovasc Disord       Date:  2016-02-12       Impact factor: 2.298

Review 7.  Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis.

Authors:  Shunquan Wu; Fuquan Wu; Yingying Ding; Jun Hou; Jingfeng Bi; Zheng Zhang
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

8.  The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers.

Authors:  Nicolette Veracruz; Bilal Hameed; Sammy Saab; Robert J Wong
Journal:  J Clin Exp Hepatol       Date:  2020-05-20

9.  AGTR1 rs3772622 gene polymorphism increase the risk of nonalcoholic fatty liver disease patients suffer coronary artery disease in Northern Chinese Han population.

Authors:  Yang Liu; Lin-Lin Lu; De-Xi Yuan; Ning Geng; Shi-Ying Xuan; Yong-Ning Xin
Journal:  Lipids Health Dis       Date:  2016-06-24       Impact factor: 3.876

10.  Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods.

Authors:  Jong Man Kim; Sang Yun Ha; Jae-Won Joh; Dong Hyun Sinn; Woo Kyung Jeong; Gyu-Seong Choi; Geum Youn Gwak; Choon Hyuck David Kwon; Young Kon Kim; Yong Han Paik; Joon Hyeok Lee; Won Jae Lee; Suk-Koo Lee; Cheol Keun Park
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.